Oculis Holding AG (Nasdaq: OCS) reported its fourth‑quarter and full‑year 2025 results on March 3 2026, posting a net loss of CHF 99.0 million (US$119.1 million) for the year, up from CHF 85.8 million (US$97.4 million) in 2024. Revenue for the quarter ended December 31 2025 was US$0.39 million, a 200 % beat over the consensus estimate of US$0.13 million, driven largely by grant income. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million (US$268.7 million) at year‑end, a substantial increase from CHF 98.7 million (US$109.0 million) in 2024, largely due to equity financings of $210.0 million in February and November 2025.
The company’s research and development expense for the quarter was CHF 13.3 million (US$16.6 million), up from CHF 11.8 million (US$13.4 million) in the same period last year, reflecting continued investment in its late‑stage pipeline. The higher R&D spend, combined with other operating costs, contributed to the larger net loss, but the robust cash position provides a runway that extends into 2029, giving the company flexibility to fund its clinical programs.
Oculis’s pipeline remains a key driver of investor interest. The company highlighted progress on OCS‑01, OCS‑02 and Privosegtor (OCS‑05). Privosegtor received FDA Breakthrough Therapy designation following Phase 2 ACUITY results, and the company is preparing for the DIAMOND‑1 and DIAMOND‑2 readouts in Q2 2026. These milestones underscore Oculis’s strategy to bring first‑in‑class eye‑drop and neuro‑protective therapies to market, positioning it for future commercial opportunities.
Management emphasized the significance of the year’s achievements. CEO Riad Sherif said, “Oculis has delivered a transformative 2025, marked by significant clinical progress across our late‑stage portfolio and a strategic expansion into neuro‑ophthalmology.” He added, “We believe Privosegtor holds immense potential as a first‑in‑class neuroprotective platform for a range of neuro‑axonal diseases.” Sherif also noted, “2026 is positioned to be a landmark year for the company with a roadmap featuring three major expected registrational milestones: the DIAMOND‑1 and DIAMOND‑2 trials readout with OCS‑01, a potential first‑in‑class eye drop in DME, anticipated in Q2, the PREDICT‑1 trial results for Licaminlimab with a precision medicine approach in dry eye disease planned in Q4, and the commencement of three registrational trials with Privosegtor as part of the PIONEER program.” He concluded, “The operational excellence and significant milestones we achieved in 2025 have uniquely positioned Oculis to drive innovation in areas of high unmet medical need, a potential market opportunity of over $30 billion, with the aim of redefining the standard of care in ophthalmology and neuro‑ophthalmology.”
Investor reaction to the earnings was muted, with analysts and the market focusing on the upcoming clinical data rather than the financial metrics. The company’s strong cash position and pipeline progress are viewed as positive, but the lack of immediate revenue growth and continued net losses keep the outlook cautious until the Q2 2026 trial readouts are available.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.